Last month, the Centers for Medicare and Medicaid (CMS) released a draft memorandum regarding its national coverage determination of the class of monoclonal antibodies directed at beta-amyloid plaque ...
In the wake of the Food and Drug Administration’s (FDA’s) controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond? We propose a coverage with ...
The Centers for Medicare & Medicaid Services (CMS) issued a ground-breaking draft national coverage decision (NCD) on January 11, 2022, for Food & Drug Administration (FDA) approved monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results